Venture Capital Archives - Page 108 of 113 - Boston Life Sciences Times

Inflammasome Therapeutics Reports Positive Phase 2 Results for K8 in Geographic Atrophy

July 17, 2026

Syntis Bio Reports Positive Initial Phase 1/1b Data for Obesity Drug SYNT-101

July 16, 2026

AdvanCell Raises $315 Million to Advance Targeted Alpha Cancer Therapies

July 15, 2026

THIS WEEK'S STORIES

Asahi Kasei Microdevices Begins Mass Production of Camera-Free Monitoring Module

July 15, 2026

Inflammasome Therapeutics Reports Positive Phase 2 Results for K8 in Geographic Atrophy

July 17, 2026

Celea Therapeutics Doses First Patient in Phase 3 IPF Trial

July 13, 2026

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Venture Capital

AdvanCell Raises $315 Million to Advance Targeted Alpha Cancer Therapies

Draig Therapeutics Raises $65 Million to Advance Neuropsychiatric Drug Pipeline

Pediatrica Health Group Raises $28 Million to Expand Pediatric Primary Care

Novartis to Acquire Sofinnova-Backed Myricx Bio in Deal Worth Up to $1.5 Billion

Anodyne Nanotech Raises $12.6 Million to Advance Weekly GLP-1 Patch

Most Read

Mirador Therapeutics Licenses Long-Acting Anti-C5a Antibody from Kira Pharmaceuticals

Bayer and Henry Ford Health Partner to Expand Patient Access to Clinical Trials

Inflammasome Therapeutics Reports Positive Phase 2 Results for K8 in Geographic Atrophy

Aqemia and Sanofi Expand AI-Driven Drug Discovery Collaboration

EDITOR PICKS

Inflammasome Therapeutics Reports Positive Phase 2 Results for K8 in Geographic Atrophy

Syntis Bio Reports Positive Initial Phase 1/1b Data for Obesity Drug SYNT-101

AdvanCell Raises $315 Million to Advance Targeted Alpha Cancer Therapies

THIS WEEK'S STORIES

Asahi Kasei Microdevices Begins Mass Production of Camera-Free Monitoring Module

Inflammasome Therapeutics Reports Positive Phase 2 Results for K8 in Geographic Atrophy

Celea Therapeutics Doses First Patient in Phase 3 IPF Trial

POPULAR CATEGORY

ABOUT US

FOLLOW US